Related Experiment Videos
Low-dose recombinant human granulocyte colony-stimulating factor therapy in children with symptomatic chronic
J C Bernini1, R Wooley, G R Buchanan
1Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas 75235-9063, USA.
Insights
Low-dose recombinant human granulocyte colony-stimulating factor (rhG-CSF) effectively treats children with chronic idiopathic neutropenia. This approach maintains neutrophil counts, resolves infections, and significantly reduces treatment costs compared to standard doses.
Area of Science:
- Hematology
- Pediatric Medicine
- Immunology
Background:
- Chronic idiopathic neutropenia (CIN) is a condition characterized by low neutrophil counts, increasing susceptibility to infections.
- Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is used to increase neutrophil production.
- Optimizing rhG-CSF dosage is crucial for managing CIN in children, balancing efficacy with cost-effectiveness.
Purpose of the Study:
- To determine the minimum effective doses of rhG-CSF for children with symptomatic CIN.
- To assess the impact of low-dose rhG-CSF on infection rates and quality of life in pediatric patients.
Main Methods:
- A prospective study involving six children with symptomatic CIN.
- rhG-CSF was administered subcutaneously, starting at 5 micrograms/kg/day, with dosage adjustments to maintain an absolute neutrophil count (ANC) above 1.0 x 10(9)/L.
- Dose-finding involved alternating increases and decreases in dosage interval and amount.
Main Results:
- All patients achieved and maintained a mean ANC > 1.0 x 10(9)/L with rhG-CSF doses ranging from 1.0 microgram/kg weekly to 5.0 micrograms/kg every other day.
- Treatment led to resolution of chronic infections, fewer new infections, and cessation of prophylactic antibiotics.
- Reducing rhG-CSF dosage decreased treatment costs by an average of 81%.
Conclusions:
- Low-dose rhG-CSF therapy (≤5 micrograms/kg every 2-7 days) is effective for symptomatic children with CIN.
- This treatment strategy is comparable in cost to antibiotic supportive care.
- Individualized minimal effective dosing of rhG-CSF offers a cost-effective and beneficial therapeutic option for pediatric CIN.
Objectives:
To prospectively define the lowest possible doses of recombinant human granulocyte colony-stimulating factor (rhG-CSF) that would benefit selected children with chronic idiopathic neutropenia whose disease was severe enough to interfere appreciably with quality of life.
Study Design:
The efficacy of low-dose rhG-CSF therapy was investigated in six children with symptomatic chronic idiopathic neutropenia. All patients received rhG-CSF, 5 micrograms/kg subcutaneously, as a single daily dose until an absolute neutrophil count (ANC) above 1.5 x 10(9)/L was observed. The rhG-CSF dosage interval and amount were then increased and decreased, respectively, in an alternating fashion until the lowest rhG-CSF dose that would maintain the ANC above 1.0 x 10(9)/L (1000/mm3) was reached.
Results:
Although the minimal dose requirements varied, all patients were able to maintain a mean ANC > 1.0 x 10(9)/L during a mean follow-up period of 14 months at doses ranging from 1.0 microgram/kg once weekly to 5.0 micrograms/kg every other day. Administration of rhG-CSF resulted in resolution of all preexisting chronic infections, reduction in the frequency of new infectious episodes, and discontinuation of prophylactic antibiotics. In all patients the ANC decreased to pretreatment values when further reduction or discontinuation of rhG-CSF therapy was attempted. By identifying the minimal effective dose in each patient, we were able to reduce the treatment cost by a mean of 81% compared with daily dosage at 5 micrograms/kg.
Conclusions:
Recombinant human granulocyte colony-stimulating factor therapy at low doses (< or = 5 micrograms/kg) every 2 to 7 days to symptomatic children with chronic idiopathic neutropenia is effective and no more costly than supportive treatment with antibiotics.